AAVantgarde Bio develops gene therapies utilizing proprietary Adeno-Associated Viral (AAV) vector technology to enable the delivery of large genes for the treatment of inherited retinal disorders. The company addresses the limitations of traditional AAV vectors, which restrict the payload size, thereby expanding the potential for genetic medicine in underserved patient populations.

Abivax is developing obefazimod, an orally administered small molecule that enhances the expression of miR-124 to stabilize immune responses in patients with chronic inflammatory diseases. This approach aims to restore homeostatic levels of cytokines and chemokines, addressing the dysregulated inflammation seen in conditions like ulcerative colitis and rheumatoid arthritis.

Actithera develops next-generation radioligand therapies by linking radioactive isotopes to precisely designed molecules for targeted cancer treatment. Their proprietary chemistry ensures prolonged tumor retention and minimized off-target effects on healthy tissues. This approach aims to deliver effective treatment with fewer cycles, enhancing patient quality of life.

Afren is an AI-powered freelance marketplace that connects businesses with a diverse on-demand workforce skilled in over 20 specialties, utilizing blockchain for secure payments and built-in project management tools. The platform addresses the challenge of finding qualified talent quickly and efficiently, offering a zero percent charge rate and 24/7 support to enhance user experience.

Alia Therapeutics is developing next-generation gene-editing therapies that utilize precise genome editing techniques to target and correct mutations responsible for rare genetic diseases. By focusing on the efficacy and durability of these treatments, the company aims to provide long-lasting cures that address the root causes of genetic disorders.

Artios Pharma develops oral small‑molecule inhibitors that target DNA damage response pathways in solid tumors, using its DcoDeR platform to align drugs with biomarker‑defined patient groups. Its lead ATR inhibitor alnodesertib, which has FDA Fast Track status for ATM‑deficient colorectal cancer, is intended to boost low‑dose chemotherapy, while the Polθ inhibitor ART6043 blocks micro‑homology‑mediated end joining and is being evaluated alone and with PARP inhibitors. The company provides combination‑ready, first‑in‑class DDR agents for oncology clinicians and pharmaceutical partners.

Arzeda utilizes Intelligent Protein Design Technology™, combining physics-based protein design and AI, to create novel proteins and enzymes that enhance product performance across various industries. This approach addresses the need for sustainable and efficient alternatives in food production, personal care, and materials, reducing environmental impact while improving functionality.

Asceneuron develops oral therapeutics that target tau pathology to treat neurodegenerative disorders, including Alzheimer’s disease and orphan tauopathies. The company addresses the high unmet medical needs in these conditions by blocking the progression of tau-related neurodegeneration.

BetterOmics is a cloud-native platform that integrates multiomic and unstructured data to provide real-time analytics for life sciences research, enhancing data sharing and collaboration across institutions. The platform addresses the challenge of siloed data by enabling efficient data orchestration and traceable insights, accelerating the pace of scientific discovery and compliance with regulatory standards.

The startup employs microbiome analysis to assess the interactions between gut bacteria and pharmaceuticals, enabling personalized drug efficacy evaluations for individual patients. This method provides specific insights into how a patient's unique microbiome profile influences their response to medications.

Bioptimus is developing a universal AI foundation model specifically for biological research, enabling researchers to leverage large-scale data analysis and predictive modeling. This technology addresses the challenge of slow and fragmented discovery processes in biomedicine by providing a cohesive platform for accelerating insights and innovations.

BIOS Health develops neural interfaces and AI technology to read and write neural data, enabling real-time analysis of the nervous system's signals. This approach addresses the malfunctioning signals that can lead to diseases, facilitating the creation of targeted pharmaceuticals and software-delivered therapies.

Biota provides a software platform that enables businesses to monitor and manage biodiversity data through advanced analytics and geospatial mapping. This technology helps organizations comply with environmental regulations and assess the ecological impact of their operations.

Borea Therapeutics develops targeted gene therapies using proprietary viral vectors to deliver precise gene transfer to specific tissues and cells. This approach addresses the need for effective treatments for patients with genetic and chronic diseases by enhancing the safety and efficacy of gene therapy.

Breath Therapeutics is developing liposomal formulations of cyclosporine A for inhalation to treat Bronchiolitis Obliterans Syndrome (BOS), a severe respiratory condition often seen in lung transplant patients. Their approach aims to improve drug delivery to the lungs, potentially enhancing treatment efficacy and patient outcomes.

The startup develops AI-driven ultrasound screening software that detects congenital heart defects in fetuses through real-time imaging analysis. This technology enhances prenatal ultrasound accuracy, enabling clinicians to make informed decisions for effective pregnancy and delivery management.

Catamaran Bio develops allogeneic CAR-NK cell therapies using genetic engineering and synthetic biology to create off-the-shelf treatments for solid tumors and other cancers. Their TAILWIND® platform enables the efficient engineering and expansion of natural killer cells, addressing the need for accessible and potent cancer therapies.

CorVent Medical develops the RESPOND® Ventilator, a lightweight and user-friendly respiratory device designed for post-ICU and home care settings. This technology eliminates the need for costly service contracts and complex setups, providing healthcare providers with a reliable solution that enhances patient care while reducing operational expenses.

Cure51 develops a clinical and molecular database that analyzes the biological features of long-term cancer survivors to identify novel therapeutic targets for drug development. By leveraging multi-omics data from biopsies, blood tests, and imaging, the company aims to enhance precision medicine and improve treatment outcomes for patients with lethal cancers.

deepc provides deepcOS, an operating system for radiology AI that centralizes deployment, orchestration, and integration of various AI solutions. This platform streamlines clinical workflows by securely connecting AI models to existing healthcare IT systems. The value lies in offering a scalable, unified infrastructure for building, evaluating, deploying, and monitoring medical imaging AI applications.

DISCO Pharmaceuticals operates a surfaceome mapping platform that identifies proteins and their communities on cancer cell surfaces, enabling the discovery of novel druggable targets. This technology addresses the limited availability of cancer-selective targets, facilitating the development of therapies that enhance treatment efficacy while minimizing side effects for patients.

éo provides an AI co-pilot that integrates into daily image screening workflows to enhance diagnostic accuracy. This system learns from individual physician expertise, encoding specialized knowledge into on-demand AI models. The platform pairs expert human judgment with machine intelligence to support superior decision-making in image-based medicine.

Freya Biosciences develops microbial immunotherapies that target immune dysregulation and inflammation associated with reproductive health conditions such as infertility, endometriosis, and preterm birth. By engineering live microbes to restore a healthy vaginal microbiome, the company aims to improve clinical outcomes for women undergoing IVF and those facing reproductive system disorders.

Galvanize is a biomedical platform company that develops proprietary pulsed electric field (PEF) technologies to selectively eliminate disease‑associated cells without thermal injury. Its integrated catheter and device systems enable minimally invasive, precision treatments for cardiac, pulmonary, oncologic, and vascular conditions, supported by a full clinical development pipeline and partnership model for hospitals and interventional physicians.